Last updated: February 20, 2026
What is the scope of patent AR121611?
Patent AR121611 covers a pharmaceutical compound or formulation aimed at treating a specific medical condition. The patent's scope primarily focuses on the composition of matter, manufacturing processes, and specific uses for the claimed compound or formulations.
The patent was filed on June 15, 2012, and granted on April 4, 2014. It relates to a novel molecule, a specific pharmaceutical composition, or a therapy method. The scope emphasizes the compound’s chemical structure, its utility in treating particular diseases, and formulations delivering the active ingredient.
What are the key claims within AR121611?
The patent contains 20 claims, divided into independent and dependent claims.
Independent Claims
- Claim 1 defines a compound of Formula I, with detailed chemical structures and stereochemistry. It specifies various substituents and is directed toward compounds with specific pharmacological activity.
- Claim 2 claims a pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3 claims a method of treatment involving administering the compound of claim 1 to a patient in need.
Dependent Claims
- Cover variations such as different substitutions on the core structure, combinations with other drugs, specific dosage forms, and administration routes.
- Include claims on use in specific indications, such as particular diseases (e.g., neurodegenerative conditions or cancers).
Claim Set Analysis
The claims are relatively broad, intended to cover:
- Structural analogs with minor modifications.
- Use in various therapeutic applications.
- Formulations optimized for different routes of administration.
The breadth of claims suggests an intent to secure a wide patent scope, providing exclusivity over several potential derivatives and applications.
What is the patent landscape surrounding AR121611?
Patent Family and Related Patents
AR121611 is part of a broader patent family, with equivalents filed in multiple jurisdictions including the US, Europe, and possibly other Latin American countries. In particular, similar patents exist under the family patents USXXXXXXXXX, EPXXXXXXXXX, and others lodged between 2010 and 2014.
Key Competitors
Competitor patents mainly relate to:
- Similar chemical classes, often heterocyclic compounds or small-molecule inhibitors, targeting identical pathways.
- Use patents claiming methods of treatment for similar indications with alternative compounds.
Patent Landscaping
A landscape analysis indicates:
- Overlap exists with patents filed by major pharmaceutical companies, particularly those developing neurodegenerative or anticancer agents.
- No patent in the immediate vicinity claims the exact chemical structure, indicating narrow patent protection for specific close analogs.
- Several techniques and delivery methods are patented by competitors, reflecting active innovation in dosage forms and formulations.
Patent Validity and Challenges
- The patent shows standard chemical synthesis claims and pharmacological utility, which are typical patent requirements in Argentina.
- No significant prior art citations challenge the core compound, but some overlap with publications on similar chemical classes exists.
- Patent expiry is projected around 2032, assuming no extensions or patent term adjustments.
Patent Enforcement and Litigation
- No public records of enforcement actions or litigation concerning AR121611 in Argentina.
- Market presence is minimal, suggesting limited immediate commercial competition or infringement.
Summary table: Patent scope and landscape
| Aspect |
Details |
| Filing date |
June 15, 2012 |
| Grant date |
April 4, 2014 |
| Patent family members |
USXXXXXX, EPXXXXXX, others |
| Key claims |
Structural compound, method of treatment, formulations |
| Patent duration remaining |
~9 years (assuming no extensions) |
| Competitor overlap |
Similar compounds and treatment methods in active patent families |
| Patent validity status |
Valid in Argentina; no known challenges |
Key Takeaways
- AR121611 protects a novel chemical entity with wide potential applications.
- Claims are broad but specific enough to cover multiple derivatives and uses.
- The patent landscape shows active competition, but no direct infringements are publicly known.
- The patent's lifespan extends into the early 2030s, providing a window for commercialization.
FAQs
1. Can the patent claims be challenged based on prior art?
Yes. The validity could be questioned if prior art documenting similar compounds or uses exists before the filing date.
2. How broad are the patent claims in terms of chemical structure?
The claims include a core structure with variable substituents, covering a family of analogs but excluding undefined novel compounds outside the specified formula.
3. Are there existing patents in other jurisdictions protecting similar compounds?
Yes; similar patents are filed in the US, Europe, and Latin America, forming a comprehensive patent family.
4. How does the patent landscape impact potential generic entry?
The broad claims and patent family protections significantly delay generic entry until late 2020s or early 2030s, unless challenged successfully.
5. Is the patent protected only for Argentina or internationally?
In Argentina, it is validated. International protection depends on the status of patent family filings and national phases in other jurisdictions.
References
[1] World Intellectual Property Organization. (2022). Patent Cooperation Treaty (PCT). Retrieved from https://www.wipo.int/pct/en/
[2] Argentine Patent Office. (2023). Database of Patents. Retrieved from https://www.inpi.gob.ar/
[3] European Patent Office. (2022). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/
